BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 12555159)

  • 1. Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction.
    Udelson JE; Konstam MA
    J Card Fail; 2002 Dec; 8(6 Suppl):S465-71. PubMed ID: 12555159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New concepts in post-infarction ventricular remodeling.
    Udelson JE; Patten RD; Konstam MA
    Rev Cardiovasc Med; 2003; 4 Suppl 3():S3-12. PubMed ID: 14564229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ventricular remodeling and its prevention in the treatment of heart failure.
    Patten RD; Udelson JE; Konstam MA
    Curr Opin Cardiol; 1998 May; 13(3):162-7. PubMed ID: 9649938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs for left ventricular remodeling in heart failure.
    Frigerio M; Roubina E
    Am J Cardiol; 2005 Dec; 96(12A):10L-18L. PubMed ID: 16399088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure.
    Kobayashi M; Machida N; Mitsuishi M; Yamane Y
    Am J Hypertens; 2004 Dec; 17(12 Pt 1):1112-9. PubMed ID: 15607617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cellular and physiologic effects of beta blockers in heart failure.
    Sabbah HN
    Clin Cardiol; 1999 Oct; 22 Suppl 5():V16-20. PubMed ID: 10526699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of angiotensin converting enzyme inhibitors on remodeling in clinical trials.
    Greenberg BH
    J Card Fail; 2002 Dec; 8(6 Suppl):S486-90. PubMed ID: 12555162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic and clinical rationales for using beta-blockers in heart failure.
    Bristow MR
    J Card Fail; 2000 Jun; 6(2 Suppl 1):8-14. PubMed ID: 10908093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure.
    Khattar RS
    Minerva Cardioangiol; 2003 Apr; 51(2):143-54. PubMed ID: 12783070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U; Wollert KC; Drexler H
    Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ventricular remodeling in heart failure and the effect of beta-blockade.
    Udelson JE
    Am J Cardiol; 2004 May; 93(9A):43B-8B. PubMed ID: 15144937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function.
    Amigoni M; Meris A; Thune JJ; Mangalat D; Skali H; Bourgoun M; Warnica JW; Barvik S; Arnold JM; Velazquez EJ; Van de Werf F; Ghali J; McMurray JJ; Køber L; Pfeffer MA; Solomon SD
    Eur Heart J; 2007 Feb; 28(3):326-33. PubMed ID: 17251259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dog model of left ventricular remodeling after myocardial infarction.
    Jugdutt BI
    J Card Fail; 2002 Dec; 8(6 Suppl):S472-5. PubMed ID: 12555160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to attenuate pathological remodeling in heart failure.
    Eapen Z; Rogers JG
    Curr Opin Cardiol; 2009 May; 24(3):223-9. PubMed ID: 19318933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, clinical characteristics, quality of life, and prognosis of patients with congestive heart failure and isolated left ventricular diastolic dysfunction.
    Badano LP; Albanese MC; De Biaggio P; Rozbowsky P; Miani D; Fresco C; Fioretti PM
    J Am Soc Echocardiogr; 2004 Mar; 17(3):253-61. PubMed ID: 14981424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ventricular remodeling in heart failure.
    Gaballa MA; Goldman S
    J Card Fail; 2002 Dec; 8(6 Suppl):S476-85. PubMed ID: 12555161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Modern therapy of cardiac insufficiency].
    Stojsić D; Jelkić N
    Med Pregl; 1999; 52(3-5):113-24. PubMed ID: 10518395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload.
    Ryan TD; Rothstein EC; Aban I; Tallaj JA; Husain A; Lucchesi PA; Dell'Italia LJ
    J Am Coll Cardiol; 2007 Feb; 49(7):811-21. PubMed ID: 17306712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE; McKinnie JJ; Greenberg SS; Giles TD
    Prog Cardiovasc Dis; 1999; 41(4):265-300. PubMed ID: 10362349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.